

Wellnex Life Limited (ASX:WNX)

Expansion into the United Kingdom: Wellnex Life receives its opening purchase order from Haleon for the Paracetamol Soft Gel Liquid Analgesic for the United Kingdom

Highlights

- Wellnex Life receives first Purchase Order for TGA registered paracetamol soft gel liquid analgesic for the UK market
- The expansion into the UK market builds on the launch of the Australian market which commenced in FY23 and the imminent launch into the United Arab Emirates
- Wellnex Life is proud to supply one of the world's largest independent consumer healthcare companies Haleon with this innovative product for use in one of the world's most trusted pain relief brands - Panadol
- The arrangement with Haleon is a testament and validation of Wellnex's business model of being the owner of healthcare brands and IP for the Australian and global markets.

Wellnex Life Limited (ASX) ("Wellnex Life" or the "Company"), is pleased to announce that Haleon has submitted the first Purchase Order (PO) for the Paracetamol Soft Gel Liquid Analgesic for the UK market.

Wellnex Life, as announced on 29 June 2023, agreed to extend the supply agreement with Haleon by increasing the product offerings and territories to take advantage of the unique and innovative TGA approved products. This builds on the successful launch in Australia where Wellnex Life has been supplying product to Haleon for one of the worlds most trusted pain relief brands - Panadol.

Haleon is a world-leading consumer healthcare company that owns brands including Panadol, Sensodyne, Voltaren, Polident, Centrum, Otrivin and Advil.

This significant step in the launch of an important market in the UK and working with one of world's largest consumer healthcare companies highlights the benefits of Wellnex's business model of identifying innovative healthcare products enabling Wellnex to secure valuable agreements with leading partners, such as Haleon.

Zack Bozinovski, Director of Wellnex, said "the launch with Haleon for the UK market for our TGA registered paracetamol soft gel liquid analgesic for one of Europe's largest markets is an important milestone for the Company. The trust and confidence imparted upon Wellnex to supply one of the world's leading pain relief brands in Panadol is a validation and testament to our Wellnex Life's business model."

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX)



For further information, please contact:

Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/